In summary, RIG-I is significantly activated by glucolipotoxicity and metaflammation, and is implicated in β cell mass loss through proliferation inhibition, leading to body decompensation in the course of T2DM. The gene discussed is RIGI; the disease is type 2 diabetes mellitus.